Insider Selling: DexCom (NASDAQ:DXCM) Director Sells 1,012 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) Director Bridgette Heller sold 1,012 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the sale, the director directly owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. This trade represents a 3.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Down 1.3%

DXCM traded down $0.75 on Thursday, reaching $57.82. 4,306,023 shares of the company’s stock were exchanged, compared to its average volume of 4,980,691. The company’s 50 day moving average is $63.99 and its 200-day moving average is $66.01. The company has a market cap of $22.31 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 1.05 and a beta of 1.40. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company’s revenue was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.32 EPS. Equities analysts predict that DexCom, Inc. will post 2.56 earnings per share for the current year.

Institutional Trading of DexCom

Several large investors have recently bought and sold shares of DXCM. Gradient Investments LLC grew its position in shares of DexCom by 13.8% during the fourth quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock worth $22,035,000 after buying an additional 40,343 shares in the last quarter. Nordea Investment Management AB grew its position in shares of DexCom by 118.6% during the fourth quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock worth $16,988,000 after buying an additional 137,986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of DexCom by 11.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock worth $14,269,000 after buying an additional 21,352 shares in the last quarter. NEOS Investment Management LLC grew its position in shares of DexCom by 58.7% during the third quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock worth $11,842,000 after buying an additional 65,066 shares in the last quarter. Finally, Peterson Wealth Services grew its position in shares of DexCom by 423.6% during the third quarter. Peterson Wealth Services now owns 28,937 shares of the medical device company’s stock worth $1,947,000 after buying an additional 23,410 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on DXCM shares. Piper Sandler reissued an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a research report on Friday, May 1st. Mizuho set a $75.00 target price on shares of DexCom in a research report on Friday, May 1st. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Finally, BTIG Research reaffirmed a “buy” rating and issued a $85.00 price objective on shares of DexCom in a research report on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $83.22.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.